Study Shows Decrease in Smoking Among Adults with Depression and Substance Use Disorders

Nov.25.2022
Study Shows Decrease in Smoking Among Adults with Depression and Substance Use Disorders
Study shows smoking rates among US adults with depression or substance use disorder have decreased, but more work needs to be done to ensure their tobacco use continues to decline.

A study entitled "Smoking trends among US adults with severe depression or substance use disorders from 2006 to 2019" is reassuring for public health experts who have long been concerned about the high smoking rates among people with mental health disorders.


Furthermore, these individuals are more likely to find it difficult to quit smoking. Therefore, they benefit greatly from additional support in quitting smoking and obtaining safer alternatives, which at least reduces their chances of developing smoking-related diseases.


A study by researchers from the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA), both under the National Institutes of Health (NIH) in the United States, suggests that this population may benefit from tobacco use prevention and cessation efforts, which have resulted in significant reductions in smoking rates among the general population.


However, researchers emphasized that disparities still exist and need to be addressed. "These declines represent a public health success story," said Wilson Compton, MD, NIDA deputy director and senior author of the study. "But there is much work to be done to ensure that tobacco use continues to decline, particularly among those with substance use disorders, depression or other mental illnesses. It is critical that healthcare providers promptly address all health issues that patients experience, not just their depression or substance use disorder. This requires integrating smoking cessation therapy into existing behavioral health therapies. The result will be longer, healthier lives for everyone.


Individuals with mental health disorders are being excluded from research. A recent study titled "The inequity of clinical trials testing smoking cessation medication: excluding smokers with mental health disorders" sought to examine the practice and reasoning behind excluding smokers with mental health disorders from such trials.


A research team analyzed the Cochrane systematic review database up to September 2020 to obtain evaluations on the use of drug therapy for smoking cessation. "We included 279 randomized controlled trials from 13 Cochrane reviews. Across all studies, 51 (18.3%) explicitly excluded participants with any mental health disorder (MHD), 152 (54.5%) conditionally excluded based on certain MHD criteria, and 76 (27.2%) did not provide sufficient information to determine inclusion or exclusion. The study found that, compared to studies on nicotine replacement therapy, research on antidepressant drugs for smoking cessation was 3.33 times more likely to conditionally exclude MHD smokers (95% CI 1.38 to 8.01, p=0.007)," the researchers reported.


In fact, their conclusion was that there wasn't enough representation of smokers with MHD (Mental Health Disorders) in clinical trials examining the safety and effectiveness of smoking cessation drugs, but there wasn't enough data collected to explain why. The study emphasized the importance of promoting the participation of this minority group in trials.


Announcement:


This article is compiled from third-party information and is intended only for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is not able to confirm the authenticity and accuracy of the article's content. The compilation of this article is solely for the purpose of industry-related communication and research.


Due to limitations in our translation ability, this article may not express the same meaning as the original. Therefore, please refer to the original article for accurate information.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign-related discussions and positions.


The copyright for the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23